Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Date:12/7/2009

NEW YORK, Dec. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced updated efficacy and safety data as well as new survival data on the clinical activity of KRX-0401 (perifosine) in combination with bortezomib (Velcade(R)) (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma. Data from the study entitled "A Multicenter Phase 1/2 Study Evaluating the Safety and Efficacy of Perifosine (KRX-0401) + Bortezomib (Velcade(R)) in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma Who Were Previously Treated with Bortezomib," was presented on Saturday, December 5th at the 51st annual meeting of the American Society of Hematology, in a poster presentation by Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute.

Dr. Richardson presented updated results from the study as follows:

Trial Results:

Eighty-four patients with relapsed/refractory multiple myeloma were enrolled in a combined Phase 1/2 study (18 patients in the Phase 1 component and 66 patients in the Phase 2 component). The patients enrolled were heavily pre-treated with a median of 5 prior lines of therapy (range 1 - 13), including;

  • 100% of patients had been treated with bortezomib (55% of the patients were previously treated with at least two bortezomib-based therapies (range 1 - 4) and 81% were previously treated with bortezomib plus dexamethasone);
  • 98% of patients were previously treated with dexamethasone;
  • 94% of patients were previously treated with lenalidomide (Revlimid(R)) and/or thalidomide (Thalomid(R)); and
  • 58% of patients had prior stem cell transplant.

Overall Response Rate (ORR), defined as the percentage of patients achieving a complete, partial or mino
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Minn. , Sept. 17, 2014 ACIST ... global market leader of advanced imaging modalities for cardiology, ... System in two live cases at the Transcatheter Cardiovascular ... The cases were presented from Medstar Washington Hospital Center ... Hospital/Columbia University Medical Center ( New York, NY ...
(Date:9/17/2014)... , Sept. 17, 2014   OTEMR, Inc. , ... Complete EHR certification, which designates that the software is ... 1 and Stage 2 Meaningful Use measures required to ... Act (ARRA).  ONETOUCH EMR 2.0 was certified on July ... of the National Coordinator-Authorized Certification Body (ONC-ACB) and is ...
(Date:9/17/2014)... , Sept. 17, 2014  Bayer HealthCare will ... Hemophilia Foundation,s 66 th Annual Meeting, which takes ... D.C.  The data, which will be shared through poster ... and patient care. Data will be presented in a ... into treatment modalities in hemophilia A patients, Bayer is ...
Breaking Medicine Technology:ACIST Launches HDi High-Definition IVUS 2ACIST Launches HDi High-Definition IVUS 3OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4
(Date:9/17/2014)... announced today that will analyze how changes in ... contribute to healthy aging. , Conducted by ... a $10 million unrestricted gift from the Amway ... identify lifestyle and environmental factors that may help ... age. WELL will be designed, conducted, and analyzed ...
(Date:9/17/2014)... latest blog post, Best Drug Rehabilitation , which offers ... a stay in rehab can make a big difference in ... member of the therapeutic care team that is making a ... and around the world: dogs. , “Studies show ... and stress levels in recovering addicts,” commented Best Drug Rehabilitation’s ...
(Date:9/17/2014)... gene manipulation these sound like the ideas ... they are components of an exciting new approach ... animal models of metastatic prostate cancer, scientists at ... of Molecular Medicine and Johns Hopkins Medical Institutions ... approach that could revolutionize doctors, ability to see ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 In Pretrial ... that “bi-weekly telephonic discovery conferences would be beneficial in ... conferences through mid-December. “At the end of December,” the ... the need for additional conferences. , “The plain ... that there is still much to be discussed as ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... Exposure in the womb to household chemicals known as ... asthma, Columbia University researchers reported in a new study. ... of developing asthma between age 5 and 11 if ... of two phthalates (pronounced thal-ates), the researchers found. The ...
Breaking Medicine News(10 mins):Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4
... breast density and its implication on the risks of breast ... has brought to the fore, the key challenges involved in ... revealed that, those with dense breasts were five times more ... with fatty tissue in the breasts. , ,Dense breasts ...
... Fat tissue around the abdomen is an abominable sight ... worse things to come. // ,Rothwell and colleague ... warn that fat around the abdomen is enemy to ... fat cells has an adverse effect on the heart. ...
... published in the Journal of Vertebral Subluxation Research ... benefits //to children suffering from learning disabilities and ... Swiss chiropractor Yannick Pauli, DC, president of the ... care of children suffering from learning and behavioral ...
... patients who were affected by parasitic infections had a ... Sclerosis is an auto immune disease which harms the ... ,Jorge Correale and Mauricio Farez of the Raul Carrea ... information, in the Annals of Neurology. A study was ...
... has entered the fray of painkillers, especially the likes of ... soreness after a heavy work out or exercise. A new ... of coffee, consumed before a work out, may ease muscle ... Patrick O'Connor, of the department of kinesiology at the University ...
... to human community by killing around 50 million people across ... the affected bodies exhibited a strange type of reaction //wherein ... to the person affected. ,American researchers reconstructed this ... lungs of the monkeys were damaged within a week. A ...
Cached Medicine News:Health News:Chiropractic Care Helps Children With Learning Disorders and Dyslexia 2Health News:Chiropractic Care Helps Children With Learning Disorders and Dyslexia 3Health News:Work-outs, Not So Much of a ‘pain’ With Caffei 2
Cold light source single outlet....
Cold light source triple outlet....
Cold light source single outlet....
... is a state of the ... source with an integrated intensity ... to connect optical fiber light ... itself from all others by ...
Medicine Products: